Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):412-416. doi: 10.26355/eurrev_201801_14189.
MiR-552 has recently been identified to be involved in tumorigenesis of colorectal cancer (CRC). The aim of this study was to determine if miR-552 could serve as a prognosis indicator for patients with CRC.
MiR-552 expression levels were detected in 183 pairs of primary CRC and their matched non-tumor tissues by qPCR. The association between miR-552 expression and clinicopathological parameters was analyzed. The survival curves were calculated by the Kaplan-Meier method. Univariate and multivariate analyses were performed to explore the prognostic significance of miR-552 expression.
We found that miR-552 expression was upregulated in CRC tumor tissues compared to their adjacent normal tissues (p < 0.01). Increased miR-552 expression was significantly associated with histological grade (p = 0.000), lymph nodes metastasis (p = 0.022) and TNM stage (p = 0.002). In addition, the patients with high miR-552 expression had a significantly worse 5-year overall survival rate than those with low miR-552 expression (p = 0.0036). Furthermore, according to univariate and multivariate analysis, elevated miR-552 was confirmed to be an independent prognostic factor for worse survival.
The current results demonstrated that high miR-552 expression was associated with poor outcomes in patients with CRC. MiR-552 may be a potential prognostic biomarker and therapeutic target in CRC patients.
最近发现 miR-552 参与了结直肠癌(CRC)的肿瘤发生。本研究旨在确定 miR-552 是否可以作为 CRC 患者的预后指标。
通过 qPCR 检测 183 对原发性 CRC 及其匹配的非肿瘤组织中的 miR-552 表达水平。分析 miR-552 表达与临床病理参数之间的关系。通过 Kaplan-Meier 法计算生存曲线。进行单因素和多因素分析以探讨 miR-552 表达的预后意义。
我们发现,与相邻正常组织相比,CRC 肿瘤组织中 miR-552 的表达上调(p<0.01)。miR-552 表达的增加与组织学分级(p=0.000)、淋巴结转移(p=0.022)和 TNM 分期(p=0.002)显著相关。此外,高 miR-552 表达的患者 5 年总生存率明显低于低 miR-552 表达的患者(p=0.0036)。此外,根据单因素和多因素分析,升高的 miR-552 被证实是影响生存的独立预后因素。
本研究结果表明,高 miR-552 表达与 CRC 患者的不良预后相关。miR-552 可能是 CRC 患者潜在的预后生物标志物和治疗靶点。